355 related articles for article (PubMed ID: 32121160)
1. Computational Cancer Cell Models to Guide Precision Breast Cancer Medicine.
Cheng L; Majumdar A; Stover D; Wu S; Lu Y; Li L
Genes (Basel); 2020 Feb; 11(3):. PubMed ID: 32121160
[TBL] [Abstract][Full Text] [Related]
2. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer.
Salter KH; Acharya CR; Walters KS; Redman R; Anguiano A; Garman KS; Anders CK; Mukherjee S; Dressman HK; Barry WT; Marcom KP; Olson J; Nevins JR; Potti A
PLoS One; 2008 Apr; 3(4):e1908. PubMed ID: 18382681
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer patient-derived scaffolds as a tool to monitor chemotherapy responses in human tumor microenvironments.
Leiva MC; Garre E; Gustafsson A; Svanström A; Bogestål Y; Håkansson J; Ståhlberg A; Landberg G
J Cell Physiol; 2021 Jun; 236(6):4709-4724. PubMed ID: 33368325
[TBL] [Abstract][Full Text] [Related]
5. Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
Huang S; Hu P; Lakowski TM
BMC Cancer; 2021 May; 21(1):648. PubMed ID: 34059012
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
[TBL] [Abstract][Full Text] [Related]
7. 3-D tumor model for in vitro evaluation of anticancer drugs.
Horning JL; Sahoo SK; Vijayaraghavalu S; Dimitrijevic S; Vasir JK; Jain TK; Panda AK; Labhasetwar V
Mol Pharm; 2008; 5(5):849-62. PubMed ID: 18680382
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel: an update of its use in advanced breast cancer.
Figgitt DP; Wiseman LR
Drugs; 2000 Mar; 59(3):621-51. PubMed ID: 10776837
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
11. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
Rouzier R; Rajan R; Wagner P; Hess KR; Gold DL; Stec J; Ayers M; Ross JS; Zhang P; Buchholz TA; Kuerer H; Green M; Arun B; Hortobagyi GN; Symmans WF; Pusztai L
Proc Natl Acad Sci U S A; 2005 Jun; 102(23):8315-20. PubMed ID: 15914550
[TBL] [Abstract][Full Text] [Related]
12. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases.
Hofman J; Skarka A; Havrankova J; Wsol V
Biochem Pharmacol; 2015 Aug; 96(3):168-78. PubMed ID: 25986883
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
[TBL] [Abstract][Full Text] [Related]
16. Personalized chemotherapy selection for breast cancer using gene expression profiles.
Yu K; Sang QA; Lung PY; Tan W; Lively T; Sheffield C; Bou-Dargham MJ; Liu JS; Zhang J
Sci Rep; 2017 Mar; 7():43294. PubMed ID: 28256629
[TBL] [Abstract][Full Text] [Related]
17. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
18. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.
Berlow NE; Rikhi R; Geltzeiler M; Abraham J; Svalina MN; Davis LE; Wise E; Mancini M; Noujaim J; Mansoor A; Quist MJ; Matlock KL; Goros MW; Hernandez BS; Doung YC; Thway K; Tsukahara T; Nishio J; Huang ET; Airhart S; Bult CJ; Gandour-Edwards R; Maki RG; Jones RL; Michalek JE; Milovancev M; Ghosh S; Pal R; Keller C
BMC Cancer; 2019 Jun; 19(1):593. PubMed ID: 31208434
[TBL] [Abstract][Full Text] [Related]
19. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
20. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.
Zoli W; Ulivi P; Tesei A; Fabbri F; Rosetti M; Maltoni R; Giunchi DC; Ricotti L; Brigliadori G; Vannini I; Amadori D
Breast Cancer Res; 2005; 7(5):R681-9. PubMed ID: 16168113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]